India, Aug. 21 -- Oruka Therapeutics Inc. (ORKA) has been one of biotech's standout performers, with its shares steadily advancing on encouraging clinical data from its pipeline of drug candidates.
This clinical-stage biotechnology company is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis (PsO) and hidradenitis suppurativa (HS).
When did we first highlight ORKA?
Oruka Therapeutics was featured on our site on September 18, 2025, when it was trading at $16.56.
Our report highlighted the key catalysts then expected for the company's lead investigational biologics, ORKA-001 and ORKA-002, which target cytokines involved in psoriasis and other inflammatory disea...